Quarterly ResultMay 7, 2026, 09:26 AM
Edgewise Therapeutics Q1 Net Loss $49.0M; Advances Clinical Programs
AI Summary
Edgewise Therapeutics reported a net loss of $49.0 million, or $0.46 per share, for the first quarter of 2026, an increase from $40.8 million, or $0.43 per share, in the same period of 2025. Research and development expenses rose to $42.7 million, primarily due to increased clinical development activity for EDG-7500 and EDG-15400. The company also announced positive long-term data for sevasemten in Becker muscular dystrophy, demonstrating sustained functional stabilization, and anticipates key clinical data readouts for EDG-7500 in Q2 2026 and pivotal GRAND CANYON results for sevasemten in Q4 2026.
Key Highlights
- Net loss was $49.0 million for Q1 2026, compared to $40.8 million for Q1 2025.
- Net loss per share was $0.46 for Q1 2026, compared to $0.43 for Q1 2025.
- Research and development expenses increased to $42.7 million in Q1 2026 from $36.8 million in Q1 2025.
- General and administrative expenses rose to $11.5 million in Q1 2026 from $9.2 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $499.6 million as of March 31, 2026.
- Announced positive long-term sevasemten data showing sustained functional stabilization in Becker muscular dystrophy up to 3.5 years.
- CIRRUS-HCM 12-week data for EDG-7500 in hypertrophic cardiomyopathy expected in Q2 2026.
- Pivotal GRAND CANYON results for sevasemten in Becker muscular dystrophy expected in Q4 2026.
Price Impact
More from EWTX